RBC Capital analyst Leonid Timashev lowered the firm’s price target on Axsome Therapeutics to $123 from $126 but keeps an Outperform rating on the shares after its Q4 results. The focus of the earnings call was the delay in the ADVANCE-2 readout – the possibility of which had been an investor debate of late – though the firm also cites continued strong launch trajectory for Auvelity that could enable $296M in 2024 sales, the analyst tells investors in a research note. RBC adds that the post-earnings stock price decline is likely an “overreaction” and that it would be “buyers on weakness”.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AXSM:
- Axsome Therapeutics Inc. Reported Earnings. Did it Beat Estimates?
- Axsome Therapeutics Updates Corporate Presentation Online
- Axsome Therapeutics reports Q4 EPS ($2.08), consensus ($1.17)
- Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Axsome Therapeutics price target raised to $112 from $90 at Mizuho